Antibody drug conjugates (ADCs) have progressed from hypothesis to approved
therapeutics in less than 30 years, and the technologies available to modify both the …

Abstract Antibody–drug conjugates (ADCs), which consist of three components, antibody,
linker, and payload, can function as “magic bullets”. These conjugates offer the ability to …

Non-native protein aggregation is a key degradation pathway of immunoglobulins. In this
work, the aggregation kinetics of an immunoglobulin gamma-1 monoclonal antibody (IgG1 …

Protein aggregates are usually formed by interactions between unfolded or partially
unfolded species, and often occur when a protein is denatured by, for example, heat or low …

Monoclonal antibodies (mAbs) as a class of therapeutic molecules are finding an increasing
demand in the biotechnology industry for the treatment of diseases like cancer and multiple …

The convergence of advanced understanding of biology with chemistry has led to a
resurgence in the development of antibody-drug conjugates (ADCs), especially with two …

Monoclonal antibodies must be both chemically and physically stable to be developed into
safe and effective drugs. Although there has been considerable progress in separately …

The analytical characterization of biopharmaceuticals is a fundamental step in the early
stages of development and prediction of their behavior in bioprocesses. Protein aggregation …

Biotherapeutics, including recombinant or plasma-derived human proteins and antibody-
based molecules, have emerged as an important class of pharmaceuticals. Aggregation and …

In recent years, antibody-drug conjugates (ADCs) have become promising antitumor agents
to be used as one of the tools in personalized cancer medicine. ADCs are comprised of a …